Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides free water and calories to correct carbohydrate depletion and osmotic diuresis. Potassium chloride replaces potassium ions to maintain cellular membrane potential, nerve impulse conduction, and muscle contraction. Sodium chloride 0.11% provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Fluid and electrolyte replenishment,Intravenous maintenance therapy for patients with low potassium and sodium requirements,Correction of hypokalemia (when chloride loss is present)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; rate and volume determined by electrolyte needs and fluid status. Typical maintenance: 1-2 m Eq/kg/day potassium chloride, administered at a rate not exceeding 10-20 m Eq/h via peripheral line or up to 40 m Eq/h via central line. This product provides 0.037% KCl (5 m Eq/L), 5% dextrose, and 0.11% Na Cl (19 m Eq/L Na+).
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Potassium: not applicable as an element; distribution half-life ~1 h. Dextrose: minutes. Sodium: regulated with t1/2 of ~1-2 h for acute load.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the Krebs cycle; potassium and sodium are not metabolized but are excreted renally.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >90% of potassium is excreted via kidneys, with minor fecal loss (~10%). Dextrose and sodium are fully metabolized or renally excreted.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Potassium: negligible (<2%). Dextrose: none. Sodium: none.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Potassium: ~0.5 L/kg (total body water). Dextrose: ~0.2 L/kg (extracellular fluid initially). Sodium: ~0.2 L/kg (extracellular space).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
IV: 100% for all components. Oral: not relevant for IV formulation.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²) unless hypokalemia is documented and close monitoring is possible. For e GFR 30-60 m L/min/1.73 m²: reduce infusion rate and total daily dose by 50% with frequent serum potassium monitoring. Use with caution in acute renal failure.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific dose adjustment required for Child-Pugh class A or B. For Child-Pugh class C: monitor serum potassium closely due to risk of hyperkalemia, especially with concomitant diuretics or renal impairment; consider lower infusion rates and total doses.
No dosage adjustment required for hepatic impairment.
Dose based on weight: usual maintenance potassium chloride 2-4 m Eq/kg/day IV infusion. For infants and children <25 kg: maximum infusion rate 0.5-1 m Eq/kg/h, not to exceed 20 m Eq/h. This product provides fixed concentrations; adjust infusion rate accordingly to avoid exceeding potassium infusion limits.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Use with caution due to age-related decline in renal function. Start at lower end of dosing range (e.g., 20-40 m Eq/day) and titrate slowly. Monitor serum potassium, renal function, and volume status frequently. Avoid rapid infusion rates.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
May cause hyperkalemia if potassium excretion is impaired or if given too rapidly,Risk of volume overload in patients with cardiac or renal impairment,Administration may cause dilutional hyponatremia and hyperglycemia,Monitor serum potassium, sodium, glucose, and fluid balance regularly,Avoid use in patients with hyperkalemia, hypernatremia, or hyperglycemia,Use caution in patients with impaired renal function or Addison's disease
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperkalemia,Hypernatremia,Hyperglycemia,Severe renal impairment with oliguria or anuria,Acute intracranial hemorrhage (due to free water load),Patients with known allergy to any component
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid excessive dietary potassium (bananas, oranges, potatoes) if serum potassium is high. This product is often used in hospital settings; patients should follow dietary restrictions as directed by their physician.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No teratogenic effects are expected when used at recommended doses. However, maternal electrolyte imbalances (e.g., hyperkalemia, hyperglycemia, hypernatremia) may indirectly affect fetal development. First trimester: No known increased risk; second/third trimester: risk of fetal acidosis or hyperglycemia if maternal levels are severely altered.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Potassium, glucose, and sodium are normal constituents of breast milk. Exogenous administration at therapeutic doses is unlikely to affect milk composition significantly. No specific M/P ratio available; minimal risk expected. However, monitor infant for signs of electrolyte imbalance or glucose dysregulation if maternal doses are high.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy may increase plasma volume and glomerular filtration rate, potentially altering electrolyte and glucose distribution. No specific dose adjustment required for potassium, dextrose, or sodium chloride at standard replacement doses, but monitor for increased requirements or hyperglycemia due to gestational insulin resistance. Adjust rate of infusion based on ongoing losses and serum levels.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This combination provides maintenance fluid and electrolytes. Use with caution in patients with renal impairment or conditions predisposing to hyperkalemia. Monitor serum potassium and glucose levels, especially in diabetic patients. Do not administer simultaneously with blood products. Check for compatibility with other additives.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution is used to provide fluids and electrolytes to your body.,Tell your doctor if you have kidney problems, diabetes, or are on a potassium-restricted diet.,Inform your healthcare provider about all medications you are taking, especially potassium supplements or diuretics.,Report any signs of allergic reaction, swelling, or shortness of breath during infusion.,Do not stop the infusion without medical advice.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose 5% provides free water and calories to correct carbohydrate depletion and osmotic diuresis. Potassium chloride replaces potassium ions to maintain cellular membrane potential, nerve impulse conduction, and muscle contraction. Sodium chloride 0.11% provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by electrolyte needs and fluid status. Typical maintenance: 1-2 m Eq/kg/day potassium chloride, administered at a rate not exceeding 10-20 m Eq/h via peripheral line or up to 40 m Eq/h via central line. This product provides 0.037% KCl (5 m Eq/L), 5% dextrose, and 0.11% Na Cl (19 m Eq/L Na+).. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No teratogenic effects are expected when used at recommended doses. However, materna. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.